BioVie Inc. (BIVI)
NASDAQ: BIVI · IEX Real-Time Price · USD
0.382
-0.003 (-0.86%)
Jul 22, 2024, 10:17 AM EDT - Market open
BioVie Employees
BioVie had 18 employees as of June 30, 2023. The number of employees increased by 5 or 38.46% compared to the previous year.
Employees
18
Change (1Y)
5
Growth (1Y)
38.46%
Revenue / Employee
n/a
Profits / Employee
-$2,065,450
Market Cap
23.40M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Biora Therapeutics | 58 |
| HCW Biologics | 45 |
| Apollomics | 45 |
| Sol-Gel Technologies | 36 |
| Nephros | 31 |
| NeuroOne Medical Technologies | 16 |
| Akso Health Group | 12 |
| Cocrystal Pharma | 12 |
BIVI News
- 17 days ago - BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 4 weeks ago - BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 4 weeks ago - BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress - GlobeNewsWire
- 5 weeks ago - Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26 - GlobeNewsWire
- 2 months ago - BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients - GlobeNewsWire
- 3 months ago - BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID - GlobeNewsWire
- 3 months ago - BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints - GlobeNewsWire
- 3 months ago - BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation - GlobeNewsWire